DingQ, ShiltzD, HossamiD, et al.The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. Expert Rev Pharmacoecon Outcomes Res, 2022; 22(8):1231–1241.
3.
Ghiti MoghadamM, VonkemanHE, Ten KloosterPM, et al.; Dutch National POET Collaboration. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: A pragmatic multicenter, open‐label randomized controlled trial. Arthritis Rheumatol, 2016; 68(8):1810–1817.
4.
LeeJ, SinghN, GraySL, et al.Optimizing medication use in older adults with rheumatic musculoskeletal diseases: Deprescribing as an approach when less may be more. ACR Open Rheumatol, 2022; 4(12):1031–1041.
5.
ChoJ, ZhouJ, LoD, et al.Palliative and end-of-life care in rheumatology: high symptom prevalence and unmet needs. In Seminars in Arthritis and Rheumatism, Vol. 49. WB Saunders; 2019, pp. 156–161.
6.
DuruN, Van Der GoesMC, JacobsJW, et al.EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis, 2013; 72(12):1905–1913.
